IP Library › Granted Patent US 12,290,556
Granted Patent B2
US 12,290,556 · App. 16/954,583 · Granted May 6, 2025

Swine influenza a virus vaccine

Inventors: Mark A. Mogler (Ames, IA); Pravina Kitikoon (Overland Park, KS); Supraja Puttamreddy (Ames, IA); Erin Strait (Spring Hill, KS); Ruud Philip Antoon Maria Segers (Boxmeer, NL); Basav Nagaraj (Wageningen, NL)
Assignee: Intervet Inc.
A61K39/145A61K49/00A61P31/16C12N9/2402A61K2039/5256A61K2039/53A61K2039/552A61K2039/55566A61K2039/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,290,556
App. No.
16/954,583
Granted
May 6, 2025
Kind
B2
Abstract

The present invention provides vectors and/or nucleic acid constructs that encode one or more influenza A virus neuraminidase (NA) antigens. The present invention also provides vaccine against influenza A virus comprising such vectors and/or nucleic acid constructs. The present invention further provides methods of making and using the vaccines alone, or in combination with other protective agents.

Claims (20)

1. A vaccine for administration to a porcine comprising a first alphavirus RNA replicon particle that encodes a first swine influenza A virus (IAV-S) neuraminidase (NA) or an antigenic fragment thereof and a second alphavirus RNA replicon particle that encodes a second IAV-S NA or an antigenic fragment thereof, and a pharmaceutically acceptable carrier; with the proviso that the vaccine neither comprises an IAV-S hemagglutinin (HA) or an antigenic fragment thereof, nor a nucleotide sequence that encodes the IAV-S HA or the antigenic fragment thereof; and wherein the first NA and the second NA comprise amino acid sequences that have 98% identity or less.

2. The vaccine of claim 1 , wherein the first NA originates from an IAV-S from a first phylogenetic cluster and the second NA originates from an IAV-S from a second phylogenetic cluster, wherein the first phylogenetic cluster and the second phylogenetic cluster are different; and wherein the first phylogenetic cluster and the second phylogenetic cluster are individually selected from the group consisting of a N1-classic cluster, a N1-pandemic cluster, N2-1998 cluster, and a N2-2002 cluster.

3. The vaccine of claim 2 , wherein the first phylogenetic cluster is selected from the group consisting of the N1-classic cluster and the N1-pandemic cluster and wherein the second phylogenetic cluster is selected from the group consisting of the N2-1998 cluster and the N2-2002 cluster.

4. The vaccine of claim 3 , wherein the first phylogenetic cluster is the N1-classic cluster and the second phylogenetic cluster is the N2-2002 cluster.

5. The vaccine of claim 2 , further comprising a third alphavirus RNA replicon particle that encodes a third NA or an antigenic fragment thereof; wherein the third NA originates from an IAV-S from a third phylogenetic cluster; and wherein the third phylogenetic cluster is different from the first phylogenetic cluster and the second phylogenetic cluster.

6. The vaccine of claim 5 , further comprising a fourth alphavirus RNA replicon particle that encodes a fourth NA or an antigenic fragment thereof; wherein the fourth NA originates from an IAV-S from a fourth phylogenetic cluster; and wherein the fourth phylogenetic cluster is different from the first phylogenetic cluster, the second phylogenetic cluster, and the third phylogenetic cluster.

7. The vaccine of claim 6 , wherein the first phylogenetic cluster is a N1-classic cluster, the second phylogenetic cluster is a N2-2002 cluster, the third phylogenetic cluster is a N1-pandemic cluster, and the fourth phylogenetic cluster is a N2-1998 cluster.

8. A vaccine comprising an alphavirus RNA replicon particle that encodes two or more swine influenza A virus (IAV-S) neuraminidases (NAs) or antigenic fragments thereof, and a pharmaceutically acceptable carrier; with the proviso that the vaccine neither comprises an IAV-S hemagglutinin (HA) or an antigenic fragment thereof, nor a nucleotide sequence that encodes the IAV-S HA or the antigenic fragment thereof; and wherein the first NA and the second NA comprise amino acid sequences that have 98% amino acid identity or less.

9. The vaccine of claim 8 , wherein the first NA originates from an IAV-S from a first phylogenetic cluster and a second NA originates from an IAV-S from a second phylogenetic cluster; wherein the first phylogenetic cluster and the second phylogenetic cluster are different; and wherein the first phylogenetic cluster and the second phylogenetic cluster are individually selected from the group consisting of a N1-classic cluster, a N1-pandemic cluster, a N2-1998 cluster, and a N2-2002 cluster.

10. The vaccine of claim 9 , wherein the first phylogenetic cluster is a N2-1998 cluster and the second phylogenetic cluster is a N2-2002 cluster.

11. The vaccine of claim 9 , wherein the first phylogenetic cluster is a N1-classic cluster and the second phylogenetic cluster is a N1-pandemic cluster.

12. The vaccine of claim 11 , further comprising a second alphavirus RNA replicon particle that encodes a third NA or antigenic fragment thereof and a fourth NA or antigenic fragment thereof; wherein the third NA originates from an IAV-S from a N2-1998 cluster and the fourth NA originates from an IAV-S from a N2-2002 cluster.

13. The vaccine of claim 1 , wherein both the first alphavirus RNA replicon particle and the second alphavirus RNA replicon particle are Venezuelan Equine Encephalitis Virus (VEEV) alphavirus RNA replicon particles.

14. A vaccine to aid in the prevention of disease in a porcine due to influenza virus comprising a Venezuelan Equine Encephalitis Virus (VEEV) alphavirus RNA replicon particle that encodes two or more swine influenza A virus (IAV-S) neuraminidases (NAs) or antigenic fragments thereof, and a pharmaceutically acceptable carrier; with the proviso that the vaccine neither comprises an IAV-S HA or an antigenic fragment thereof, nor a nucleotide sequence that encodes the IAV-S HA or the antigenic fragment thereof.

15. The vaccine of claim 8 , which is a nonadjuvanted vaccine.

16. The vaccine of claim 8 , that comprises an adjuvant selected from the group consisting of an oil-in-water emulsion with 2.5-50% (v/v) mineral oil, and a biodegradable oil mixed with an oil-in-water emulsion with 2.5-50% (v/v) mineral oil.

17. The vaccine of claim 16 , wherein the biodegradable oil is dl-α-tocopheryl acetate and the mineral oil is a liquid paraffin.

18. A method of immunizing a porcine against a swine influenza A virus comprising administering to the porcine an immunologically effective amount of the vaccine of claim 16 .

19. A method of immunizing a porcine against a swine influenza A virus comprising administering to the porcine an immunologically effective amount of the vaccine of claim 14 .

20. The vaccine of claim 8 , wherein the alphavirus RNA replicon particle is a Venezuelan Equine Encephalitis Virus (VEEV) alphavirus RNA replicon particle.

Assignments (2)
CHANGE OF ADDRESS Recorded Sep 26, 2023
From: INTERVET INC.
To: INTERVET INC.
Reel/Frame 065028/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2020
From: MOGLER, MARK A.; KITIKOON, PRAVINA; PUTTAMREDDY, SUPRAJA; STRAIT, ERIN; SEGERS, RUUD PHILIP ANTOON MARIA; NAGARAJ, BASAV
To: INTERVET INC.
Reel/Frame 052959/0861 →
Continuity (2)
Provisional Application 62607101 · Dec 18, 2017
Related Publication 20200330585A1 · Oct 22, 2020
References Cited (80)
US 8460913B2 · Kamrud et al. · 2013 [cited by applicant]
US 8597662B2 · Jacobs et al. · 2013 [cited by applicant]
US 8678184B2 · Kraus et al. · 2014 [cited by applicant]
US 8808686B2 · Del Giudice et al. · 2014 [cited by applicant]
US 9084768B2 · Jacobs et al. · 2015 [cited by applicant]
US 9441247B2 · Rayner et al. · 2016 [cited by applicant]
US 9730997B2 · Perri et al. · 2017 [cited by applicant]
US 9764024B2 · Fomsgaard et al. · 2017 [cited by applicant]
US 10619169B2 · Mundt et al. · 2020 [cited by applicant]
US 10905756B2 · Eichmeyer et al. · 2021 [cited by applicant]
US 20090104226A1 · Perri et al. · 2009 [cited by applicant]
JP 2008500399A · 2008 [cited by applicant]
WO 2005007689A1 · 2005 [cited by applicant]
WO WO06078294 · 2006 [cited by examiner]
WO 2006082398A2 · 2006 [cited by applicant]
WO 2008033966A2 · 2008 [cited by applicant]
WO 2009014919A2 · 2009 [cited by applicant]
WO 2014005958A1 · 2014 [cited by applicant]
WO 2016137929A1 · 2016 [cited by applicant]
WO 2017123976A1 · 2017 [cited by applicant]
WO 2018054822A1 · 2018 [cited by applicant]
WO 2019179966A1 · 2019 [cited by applicant]
WO 2019191257A1 · 2019 [cited by applicant]
WO 2020035609A2 · 2020 [cited by applicant]
Walker et al., H1N1 Antibody Persistence 1 Year After Immunization With an Adjuvanted or Whole-Virion Pandemic Vaccine and Immunogenicity and Reactogenicity of Subsequent Seasonal Influenza vaccine: A multicenter follow… [cited by examiner]
Friedewald, Adjuvants in Immunization with Influenza virus vaccines, J Exp Med. 1944, vol. 80, No. 6, pp. 477-491. [cited by examiner]
Anderson, Tavis K. et al., A Phylogeny-Based Global Nomenclature System and Automated Annotation Tool for H1 Hemagglutinin Genes from Swine Influenza A Viruses, mSphere, 2016, 1-14, 1(6) e00275-16. [cited by applicant]
Anderson, Tavis K. et al., Population dynamics of cocirculating swine influenza A viruses in the United States from 2009 to 2012, Influenza and Other Respiratory Viruses, 2013, 42-51, 7 (Suppl. 4). [cited by applicant]
Bodewes, Rogier et al., Animal models for the preclinical evaluation of candidate influenza vaccines, Expert Rev. Vaccines, 2010, 59-72, 9(1). [cited by applicant]
Bosch, et al., Recombinant Soluble, Multimeric HA and NA Exhibit Distinctive Types of Protection against Pandemic Swind-Origin 2009 A(H1N1) Influenza Virus Infection in Ferrets, Journal of Virology, Oct. 2010, pp. 10366… [cited by applicant]
Bredenbeek, Peter J. et al., Sindbis Virus Expression Vectors: Packaging of RNA Replicons by Using Defective Helper RNAs, Journal of Virology, 1993, 6439-6446, 67(11). [cited by applicant]
Brett, Ian C. et al., Immunization against influenza A virus: Comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine mo… [cited by applicant]
Gao, Shibo et al., The genomic evolution of H1 influenza A viruses from swine detected in the United States between 2009 and 2016, Journal of General Virology, 2017, 2001-2010, 98(8). [cited by applicant]
Hessel, Annett et al., A Pandemic Influenza H1N1 Live Vaccine Based on Modified Vaccinia Ankara Is Highly Immunogenic and Protects Mice in Active and Passive Immunizations, PLoS One, 2010, 1-11, 5(8):e12217. [cited by applicant]
Holtkamp, Derald et al., The economic cost of major health challenges in large US swine production systems, The American Association of Swine Veterinarians Annual Meeting, 2007, 85-89, N/A. [cited by applicant]
Johansson, B.E. et al., Immunization with purified N1 and N2 influenza virus neuraminidases demonstrates cross-reactivity without antigenic competition, Proc. Natl. Acad. Sci. USA, 1994, 2358-2361, 91(6). [cited by applicant]
Kamrud, K.I. et al., Development and characterization of promoterless helper RNAs for the production of alphavirus replicon particle, Journal of General Virology, 2010, 1723-1727, 91(Pt 7). [cited by applicant]
Katoh, Kazutaka et al., MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability, Mol. Biol. Evol., 2013, 772-780, 30(4). [cited by applicant]
Katoh, Kazutaka et al., MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform, Nucleic Acids Research, 2002, 3059-3066, 30(14). [cited by applicant]
Kilbourne, Edwin D. et al., Protection of Mice with Recombinant Influenza Virus Neuraminidase, The Journal of Infectious Diseases, 2004, 459-461, 189(3). [cited by applicant]
Kitikoon, Pravina et al., Hemagglutinin Inhibition Assay with Swine Sera, Methods in Molecular Biology, 2014, 295-301, 1161. [cited by applicant]
Klingbeil, Katharina et al., Protection of pigs against pandemic swine origin H1N1 influenzaA virus infection by hemagglutinin- or neuraminidase-expressingattenuated pseudorabies virus recombinants, Virus Research, 2015… [cited by applicant]
Krueger, Whitney S. et al., Swine Influenza Virus Infections in Man, Curr Top Microbiol Immunol, 2013, 201-225, 370. [cited by applicant]
Kumar, Sudhir et al., MEGA-CC: computing core of molecular evolutionary genetics analysis program for automated and iterative data analysis, Bioinformatics, 2012, 2685-2686, 28. [cited by applicant]
Kuntz-Simon, G. et al., Genetic and Antigenic Evolution of Swine Influenza Viruses in Europe and Evaluation of Their Zoonotic Potential, Zoonoses and Public Health, 2009, 310-325, 56(6-7). [cited by applicant]
Kyriakis, C.S. et al., Efficacy of commercial swine influenza vaccines against challenge with a recent European H1N1 field isolate, Veterinary Microbiology, 2010, 67-74, 144(1-2). [cited by applicant]
Lee, Jee Hoon et al., Efficacy of swine influenza A virus vaccines against an H3N2 virus variant, The Canadian Journal of Veterinary Research, 2007, 207-212, 71(3). [cited by applicant]
Liljestrom, P. et al., A new generation of animal cell expression vectors based on the semliki forest virus replicon, Biotechnology, 1991, pp. 1356-1361, 9. [cited by applicant]
Mehle, Andrew, Unusual Influenza A Viruses in Bats, Viruses, 2014, 3438-3440, 6(9). [cited by applicant]
Memoli, Matthew J. et al., Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model, mBio, 2016, 1-12, 7(2):e00417-16. [cited by applicant]
Monto, Arnold S. et al., Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection, The Journal of Infectious Diseases, 2015, 1191-1199, 212(8). [cited by applicant]
Murphy, Brian R. et al., Association of Serum Anti-Neuraminidase Antibody with Resistance to Influenza in Man, The New England Journal of Medicine, 1972, 1329-1332, 286(25). [cited by applicant]
Nayak, Baibaswata et al., Contributions of the Avian Influenza Virus HA, NA, and M2 Surface Proteins to the Induction of Neutralizing Antibodies and Protective Immunity, Journal of Virology, 2010, 2408-2420, 84(5). [cited by applicant]
Nelson, M, Evolution of Novel Reassortant A/H3N2 Influenza Viruses in North American Swine and Humans, 2009-2011, Journal of Virology, 2012, 8872-8878, vol. 86, No. 16. [cited by applicant]
Nelson, Martha I. et al., Reverse zoonosis of influenza to swine: new perspectives on the human-animal interface, Trends in Microbiol., 2015, 142-153, 23(3). [cited by applicant]
Pavlova, S.P. et al., Protection of chickens against H5N1 highly pathogenic avian virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase… [cited by applicant]
Price, Morgan N. et al., FastTree 2—Approximately Maximum-Likelihood Trees for Large Alignments, PLoS One, 2010, 1-10, 5(3): e9490. [cited by applicant]
Pushko, Peter et al., Replicon-Helper Systems from Attenuated Venezuelan Equine Encephalitis Virus: Expression of Heterologous Genes in Vitro and Immunization against Heterologous Pathogens in Vivo, Virology, 1997, 389-… [cited by applicant]
Sandbulte, Matthew R. et al., Analyzing Swine Sera for Functional Antibody Titers Against Infl uenza A Neuraminidase Proteins Using an Enzyme-Linked Lectin Assay (ELLA), Methods in Molecular Biology, 2014, 337-345, 1161. [cited by applicant]
Sylte, Matthew J. et al., Influenza neuraminidase antibodies provide partial protection for chickens against high pathogenic avian influenza infection, Vaccine, 2007, 3763-3772, 25(19). [cited by applicant]
Tong, Suxiang et al., A distinct lineage of influenza A virus from bats, PNAS, 2012, 4269-4274, 109(11). [cited by applicant]
Tripp, Ralph A. et al., Animal Models for Evaluation of Influenza Vaccines, Current Topics in Microbiology and Immunology, 2009, 397-412, 333. [cited by applicant]
Vander Veen, RL et al., Alphavirus replicon vaccines, Animal Health Research Reviews, 2012, 1-9, vol. 13, No. 1. [cited by applicant]
Vander Veen, RL et al., Safety, immunogenicity, and efficacy of an alphavirus replicon-based swine influenza virus hemagglutinin vaccine, Vaccine, 2012, 1944-1950, vol. 30, No. 11. [cited by applicant]
Vincent, Amy L. et al., Efficacy of inactivated swine influenza virus vaccines against the 2009 A/H1N1 influenza virus in pigs, Vaccine, 2010, 2782-2787, 28(15). [cited by applicant]
Watson, Simon J. et al., Molecular Epidemiology and Evolution of Influenza Viruses Circulating within European Swine between 2009 and 2013, Journal of Virology, 2015, 9920-9931, 89(19). [cited by applicant]
Webster, Robert G. et al., Evolution and Ecology of Influenza A Viruses, Microbiological Reviews, 1992, 152-179, 56(1). [cited by applicant]
Kuznetsov, V.I., et al., Guideline for Diagnosis and Treatment of Swine Influenza, Peoples' Friendship University of Russia, 2009, 3-16, N/A. [cited by applicant]
Kuznetsov, V.I., et al., Guideline for Diagnosis and Treatment of Swine Influenza, Peoples' Friendship University of Russia, 2009, 3-16, N/A; English translation. [cited by applicant]
Abstract corrected by the examiner on 1 page. [cited by applicant]
Abstract corrected by the examiner on 1 page, machine translation. [cited by applicant]
Jagadesh, Anitha et al., Influenza virus neuraminidase (NA): a target for antivirals and vaccines, Arch Virol, 2016, 2087-2094, 161. [cited by applicant]
Kitikoon et al, Swine influenza matrix 2 (M2) protein contributes to protection against infection with different H1 swine influenza virus (SIV) isolates, Vaccine, 2010, 523-531, 28. [cited by applicant]
Li et al., The epidemiology of swine influenza, Animal Diseases, 2021, 1-14. [cited by applicant]
Li, Haozhou et al., Novel Capsid-Specific Single-Domain Antibodies with Broad Foot-and-Mouth Disease Strain Recognition Reveal Differences in Antigenicity of Virions, Empty Capsids, and Virus-Like Particles, Vaccines, 2… [cited by applicant]
Rajao, et al., Pathogenesis and Vaccination of Influenza A Virus in Swine, Influenza Pathogenesis and Control—vol. I, 2014, 307-326, 385. [cited by applicant]
Rose, et al., Dynamics of influenza A virus infections in permanently infected pig farms: evidence of recurrent Infections, circulation of several swine influenza viruses and reassortment events, Veterinary Research, 20… [cited by applicant]
Vincent, Amy I. et al., Influenza A virus vaccines for swine, Veterinary Microbiology, 2017, 35-44, 206. [cited by applicant]
Eichelberger, Maryna C. et al., Influenza Neuraminidase as a Vaccine Antigen, Influenza Pathogenesis and Control-vol. II, II, 275-299, 2014. [cited by applicant]
Sylte, Matthew J. et al., Influenza neuraminidase as a vaccine antigen, Curr Top Microbiol Immunol, 333, 227-241, 2009. [cited by applicant]